MBRX

Moleculin Biotech, Inc.

8.06

USD

-0.60

-6.93%

Nov 10, 15:59 UTC -5

Closed

After-Market

8.38

+0.31

+3.91%

Moleculin Biotech, Inc. (MBRX) Earnings

MBRX Earnings Reports

Positive Surprise Ratio

MBRX beat 21 of 36 last estimates.

58%

Next Report

Tomorrow

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$9.04

Implied change from Q2 26 (Revenue/ EPS)

-67.71%

Implied change from Q3 25 (Revenue/ EPS)

-97.34%

Moleculin Biotech, Inc. earnings per share and revenue

On Aug 13, 2026, MBRX reported earnings of -28.00 USD per share (EPS) for Q2 26, beating the estimate of -31.68 USD, resulting in a 11.64% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +7.16% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -9.04 USD, with revenue projected to reach -- USD, implying an decrease of -67.71% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

CalciMedica, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$1.30

Actual

-$0.72

Surprise

+44.64%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

FAQ

What were Moleculin Biotech, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Moleculin Biotech, Inc. reported EPS of -$28.00, beating estimates by 11.64%, and revenue of $0.00, 0% as expectations.

How did the market react to Moleculin Biotech, Inc.'s Q2 2026 earnings?

The stock price moved up 7.16%, changed from $0.57 before the earnings release to $0.61 the day after.

When is Moleculin Biotech, Inc. expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for Moleculin Biotech, Inc.'s next earnings report?

Based on -- analysts, Moleculin Biotech, Inc. is expected to report EPS of -$9.04 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.